Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Moreno HLG, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2019 Jun 3. doi: 10.1056/NEJMoa1904819. [Epub ahead of print]

PMID:
31157962
2.

Analytical validation of a standardized scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicenter collaboration.

Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hugh JC, Kos Z, Laenkholm AV, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF, McShane LM, Dowsett M; International Ki67 in Breast Cancer Working Group of the Breast International Group North American Breast Cancer Group (BIG-NABCG).

Histopathology. 2019 Apr 24. doi: 10.1111/his.13880. [Epub ahead of print]

PMID:
31017314
3.

Splicing factor ESRP1 controls ER-positive breast cancer by altering metabolic pathways.

Gökmen-Polar Y, Neelamraju Y, Goswami CP, Gu Y, Gu X, Nallamothu G, Vieth E, Janga SC, Ryan M, Badve SS.

EMBO Rep. 2019 Feb;20(2). pii: e46078. doi: 10.15252/embr.201846078. Epub 2019 Jan 21.

PMID:
30665944
4.

EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer.

Buechler SA, Gökmen-Polar Y, Badve SS.

Breast. 2019 Feb;43:74-80. doi: 10.1016/j.breast.2018.11.006. Epub 2018 Nov 17.

PMID:
30502641
5.

Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer.

Gökmen-Polar Y, True JD, Vieth E, Gu Y, Gu X, Qi GD, Mosley AL, Badve SS.

PLoS One. 2018 Oct 2;13(10):e0204658. doi: 10.1371/journal.pone.0204658. eCollection 2018.

6.

EarlyR: A Robust Gene Expression Signature for Predicting Outcomes of Estrogen Receptor-Positive Breast Cancer.

Buechler SA, Gökmen-Polar Y, Badve SS.

Clin Breast Cancer. 2019 Feb;19(1):17-26.e8. doi: 10.1016/j.clbc.2018.07.011. Epub 2018 Jul 17.

PMID:
30097312
7.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

8.

Giant Cell Polymyositis and Myocarditis in a Patient With Thymoma and Myasthenia Gravis: A Postviral Autoimmune Process?

Priemer DS, Davidson DD, Loehrer PJ, Badve SS.

J Neuropathol Exp Neurol. 2018 Aug 1;77(8):661-664. doi: 10.1093/jnen/nly041.

PMID:
29850899
9.

Higher Absolute Lymphocyte Counts Predict Lower Mortality from Early-Stage Triple-Negative Breast Cancer.

Afghahi A, Purington N, Han SS, Desai M, Pierson E, Mathur MB, Seto T, Thompson CA, Rigdon J, Telli ML, Badve SS, Curtis CN, West RB, Horst K, Gomez SL, Ford JM, Sledge GW, Kurian AW.

Clin Cancer Res. 2018 Jun 15;24(12):2851-2858. doi: 10.1158/1078-0432.CCR-17-1323. Epub 2018 Mar 26.

10.

Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studies.

Rakovitch E, Gray R, Baehner FL, Sutradhar R, Crager M, Gu S, Nofech-Mozes S, Badve SS, Hanna W, Hughes LL, Wood WC, Davidson NE, Paszat L, Shak S, Sparano JA, Solin LJ.

Breast Cancer Res Treat. 2018 Jun;169(2):359-369. doi: 10.1007/s10549-018-4693-2. Epub 2018 Jan 31.

11.

The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance.

Suarez CD, Wu J, Badve SS, Sparano JA, Kaliney W, Littlepage LE.

Oncotarget. 2017 Jul 17;8(65):108534-108547. doi: 10.18632/oncotarget.19308. eCollection 2017 Dec 12.

12.

Paraneoplastic Syndromes and Thymic Malignancies: An Examination of the International Thymic Malignancy Interest Group Retrospective Database.

Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelee HA, Badve SS.

J Thorac Oncol. 2018 Mar;13(3):436-446. doi: 10.1016/j.jtho.2017.11.118. Epub 2017 Nov 27.

13.

Single-cell heterogeneity in ductal carcinoma in situ of breast.

Gerdes MJ, Gökmen-Polar Y, Sui Y, Pang AS, LaPlante N, Harris AL, Tan PH, Ginty F, Badve SS.

Mod Pathol. 2018 Mar;31(3):406-417. doi: 10.1038/modpathol.2017.143. Epub 2017 Nov 17.

14.

Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.

Fusco N, Geyer FC, De Filippo MR, Martelotto LG, Ng CK, Piscuoglio S, Guerini-Rocco E, Schultheis AM, Fuhrmann L, Wang L, Jungbluth AA, Burke KA, Lim RS, Vincent-Salomon A, Bamba M, Moritani S, Badve SS, Ichihara S, Ellis IO, Reis-Filho JS, Weigelt B.

Mod Pathol. 2016 Nov;29(11):1292-1305. doi: 10.1038/modpathol.2016.134. Epub 2016 Aug 5.

15.

Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.

Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Enos RA, Fineberg S, Focke CM, Gao D, Gown AM, Grabau D, Gutierrez C, Hugh JC, Kos Z, Lænkholm AV, Lin MG, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Viale G, Hayes DF, McShane LM, Dowsett M.

NPJ Breast Cancer. 2016 May 18;2:16014. doi: 10.1038/npjbcancer.2016.14. eCollection 2016.

16.

Reply to C. Shah et al.

Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE.

J Clin Oncol. 2016 May 20;34(15):1824-5. doi: 10.1200/JCO.2016.66.4714. Epub 2016 Mar 21. No abstract available.

PMID:
27001578
17.

A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas.

Radovich M, Solzak JP, Hancock BA, Conces ML, Atale R, Porter RF, Zhu J, Glasscock J, Kesler KA, Badve SS, Schneider BP, Loehrer PJ.

Br J Cancer. 2016 Feb 16;114(4):477-84. doi: 10.1038/bjc.2015.425. Epub 2016 Jan 14.

18.

Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.

Perez EA, Ballman KV, Tenner KS, Thompson EA, Badve SS, Bailey H, Baehner FL.

JAMA Oncol. 2016 Jan;2(1):56-64. doi: 10.1001/jamaoncol.2015.3239.

19.

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Perez EA, Olson JA Jr, Zujewski J, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin P, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Atkins JN, Berenberg JL, Sledge GW.

N Engl J Med. 2015 Nov 19;373(21):2005-14. doi: 10.1056/NEJMoa1510764. Epub 2015 Sep 27.

20.

Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC).

Adams S, Goldstein LJ, Sparano JA, Demaria S, Badve SS.

Oncoimmunology. 2015 Jul 27;4(9):e985930. eCollection 2015 Sep.

21.

Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study.

Solin LJ, Gray R, Hughes LL, Wood WC, Lowen MA, Badve SS, Baehner FL, Ingle JN, Perez EA, Recht A, Sparano JA, Davidson NE.

J Clin Oncol. 2015 Nov 20;33(33):3938-44. doi: 10.1200/JCO.2015.60.8588. Epub 2015 Sep 14.

22.

An international study to increase concordance in Ki67 scoring.

Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM, McShane LM, Enos RA, Badve SS, Bane AL, Borgquist S, Fineberg S, Lin MG, Gown AM, Grabau D, Gutierrez C, Hugh JC, Moriya T, Ohi Y, Osborne CK, Penault-Llorca FM, Piper T, Porter PL, Sakatani T, Salgado R, Starczynski J, Lænkholm AV, Viale G, Dowsett M, Hayes DF, Nielsen TO.

Mod Pathol. 2015 Jun;28(6):778-86. doi: 10.1038/modpathol.2015.38. Epub 2015 Feb 20.

23.

The birth of an adenoid cystic carcinoma.

Fusco N, Guerini-Rocco E, Schultheis AM, Badve SS, Reis-Filho JS, Weigelt B.

Int J Surg Pathol. 2015 Feb;23(1):26-7. doi: 10.1177/1066896914548795. Epub 2014 Sep 3. No abstract available.

24.

Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, Martino S, Wang M, Jones VE, Saphner TJ, Wolff AC, Wood WC, Davidson NE, Sledge GW, Sparano JA, Badve SS.

J Clin Oncol. 2014 Sep 20;32(27):2959-66.

25.

ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting.

Marx A, Ströbel P, Badve SS, Chalabreysse L, Chan JK, Chen G, de Leval L, Detterbeck F, Girard N, Huang J, Kurrer MO, Lauriola L, Marino M, Matsuno Y, Molina TJ, Mukai K, Nicholson AG, Nonaka D, Rieker R, Rosai J, Ruffini E, Travis WD.

J Thorac Oncol. 2014 May;9(5):596-611. doi: 10.1097/JTO.0000000000000154.

26.

Opportunistic infections in a patient with HIV and thymoma.

Leathers CA, Azar MM, Badve SS, Roth TD, Loehrer PJ, Nelson RP Jr.

J Allergy Clin Immunol Pract. 2013 Jul-Aug;1(4):413-5. doi: 10.1016/j.jaip.2013.03.017. Epub 2013 May 27. No abstract available.

PMID:
24565551
27.

The utility of immunostaining for NUT, GAGE7 and NY-ESO-1 in the diagnosis of spermatocytic seminoma.

Kao CS, Badve SS, Ulbright TM.

Histopathology. 2014 Jul;65(1):35-44. doi: 10.1111/his.12365. Epub 2014 Feb 28.

PMID:
24393139
28.

Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial.

Schneider BP, Gray RJ, Radovich M, Shen F, Vance G, Li L, Jiang G, Miller KD, Gralow JR, Dickler MN, Cobleigh MA, Perez EA, Shenkier TN, Vang Nielsen K, Müller S, Thor A, Sledge GW Jr, Sparano JA, Davidson NE, Badve SS.

Clin Cancer Res. 2013 Mar 1;19(5):1281-9. doi: 10.1158/1078-0432.CCR-12-3029. Epub 2013 Jan 22.

29.

Counterpoint: cancer stem cells: nonbelievers' viewpoint.

Gökmen-Polar Y, Badve SS.

Clin Chem. 2013 Jan;59(1):208-10. doi: 10.1373/clinchem.2012.185637. Epub 2012 Nov 7. No abstract available.

30.

Impact of preanalytic factors on the design and application of integral biomarkers for directing patient therapy.

Hewitt SM, Badve SS, True LD.

Clin Cancer Res. 2012 Mar 15;18(6):1524-30. doi: 10.1158/1078-0432.CCR-11-2204.

31.

A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.

Carlson RW, O'Neill A, Vidaurre T, Gomez HL, Badve SS, Sledge GW.

Breast Cancer Res Treat. 2012 Jun;133(3):1049-56. doi: 10.1007/s10549-012-1997-5. Epub 2012 Mar 15.

32.

Immune-mediated diseases and immunodeficiencies associated with thymic epithelial neoplasms.

Khawaja MR, Nelson RP Jr, Miller N, Badve SS, Loehrer E, Czader M, Perkins SM, Kesler K, Loehrer PJ Sr.

J Clin Immunol. 2012 Jun;32(3):430-7. doi: 10.1007/s10875-011-9644-1. Epub 2012 Jan 8.

PMID:
22228568
33.

Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.

Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA; Cancer and Leukemia Group B Pathology Committee.

J Clin Oncol. 2011 Jun 1;29(16):2282-90. doi: 10.1200/JCO.2010.33.2023. Epub 2011 Apr 25.

34.

High-level expression of forkhead-box protein A1 in metastatic prostate cancer.

Jain RK, Mehta RJ, Nakshatri H, Idrees MT, Badve SS.

Histopathology. 2011 Apr;58(5):766-72. doi: 10.1111/j.1365-2559.2011.03796.x. Epub 2011 Mar 14.

PMID:
21401706
35.

Prevalence and classification of spontaneous mammary intraepithelial lesions in dogs without clinical mammary disease.

Mouser P, Miller MA, Antuofermo E, Badve SS, Mohammed SI.

Vet Pathol. 2010 Mar;47(2):275-84. doi: 10.1177/0300985809358603. Epub 2010 Jan 22.

PMID:
20106771
36.

Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory.

Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA.

J Clin Oncol. 2008 May 20;26(15):2473-81. doi: 10.1200/JCO.2007.13.6424. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472. Perez, Edith D [corrected to Perez, Edith A].

PMID:
18487567
37.

Prostanoid receptor EP1 expression in breast cancer.

Thorat MA, Morimiya A, Mehrotra S, Konger R, Badve SS.

Mod Pathol. 2008 Jan;21(1):15-21. Epub 2007 Sep 28.

38.

Development of hollow/porous calcium pectinate beads for floating-pulsatile drug delivery.

Badve SS, Sher P, Korde A, Pawar AP.

Eur J Pharm Biopharm. 2007 Jan;65(1):85-93. Epub 2006 Jul 21.

PMID:
16971097
39.

Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors.

Andreyev HJ, Scott-Mackie P, Cunningham D, Nicolson V, Norman AR, Badve SS, Iveson A, Nicolson MC.

J Clin Oncol. 1995 Jun;13(6):1486-92.

PMID:
7751896
40.

Alpha-fetoprotein production by rhabdomyosarcoma of the urinary bladder.

Badve SS, Saxena R, Soman CS, Kiri VM, Raghuvanshi SR, Patoria NK.

Indian J Cancer. 1992 Dec;29(4):177-80.

PMID:
1284051
41.

Intraductal hepatocellular carcinoma with normal liver--case report.

Badve SS, Saxena R, Wagholikar UL.

Indian J Cancer. 1991 Sep;28(3):165-7.

PMID:
1723965
42.

Uraemia--a rare presentation of non-Hodgkin's lymphoma.

Badve SS, Saxena R, Wagholikar UL.

Indian J Cancer. 1990 Dec;27(4):217-9. Review.

PMID:
2090577

Supplemental Content

Loading ...
Support Center